Novartis manufactures Entresto [1]. Entresto, also known by its generic name sacubitril/valsartan, is a prescription medication used to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure [2].
What is Entresto used for?
Entresto is indicated for patients with symptomatic chronic heart failure with reduced ejection fraction [2]. It works by helping to relax blood vessels, which lowers blood pressure and makes it easier for the heart to pump blood [3].
When did Entresto first become available?
Entresto received its initial FDA approval in July 2015 [4].
How does Entresto work in the body?
Entresto is a combination drug containing sacubitril and valsartan. Sacubitril is a neprilysin inhibitor, which works by increasing the levels of natriuretic peptides in the body. Valsartan is an angiotensin II receptor blocker (ARB), which blocks the action of angiotensin II, a hormone that constricts blood vessels and raises blood pressure [5]. By combining these mechanisms, Entresto helps to improve the heart's function and reduce the workload on the cardiovascular system [3].
What are the common side effects of Entresto?
Common side effects of Entresto can include dizziness, fatigue, nausea, and cough [3]. Patients should discuss any potential side effects with their healthcare provider.
Are there any alternatives to Entresto for heart failure?
Other medications used to treat heart failure include ACE inhibitors, ARBs, beta-blockers, and mineralocorticoid receptor antagonists [6]. The choice of medication depends on the individual patient's condition and medical history.
Who holds the patents for Entresto?
Novartis holds patents related to Entresto [7]. Information on specific patent expiry dates and any related legal challenges can be found through resources like DrugPatentWatch.com [7].
What is the price of Entresto?
The cost of Entresto can vary depending on insurance coverage and pharmacy. Patients may find pricing information through their insurance provider or by consulting pharmacies.
Are there generic versions of Entresto available?
As of now, there are no generic versions of Entresto approved by the FDA. The medication is still under patent protection [7].
What is the regulatory status of Entresto?
Entresto is approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) [4] and the European Medicines Agency (EMA) [8].
What clinical data supports Entresto's use?
The efficacy and safety of Entresto were established in clinical trials, most notably the PARADIGM-HF study, which demonstrated a significant reduction in cardiovascular mortality and heart failure hospitalizations compared to an ACE inhibitor [9].
What are patient concerns regarding Entresto?
Patients may have concerns about the effectiveness of Entresto, potential side effects, and the cost of treatment. Open communication with healthcare providers is important for addressing these concerns [3].
What is the mechanism of action for Entresto?
Entresto acts as an angiotensin receptor-neprilysin inhibitor (ARNI). Sacubitril inhibits neprilysin, an enzyme that breaks down natriuretic peptides, thereby increasing their levels. Valsartan blocks the angiotensin II type 1 receptor [5].
When does Entresto's patent protection expire?
Patent protection for medications like Entresto typically lasts for a defined period. Specific patent expiry dates and potential challenges can be tracked through specialized databases [7].
Who are Entresto's main competitors in the heart failure market?
The market for heart failure treatments is competitive, with various drug classes and individual medications vying for market share. Companies develop and market drugs that target different pathways involved in heart failure [6].
Can biosimilars be developed for Entresto before patent expiry?
The development of biosimilars is typically considered after patent expiry for biologics. For small molecule drugs like Entresto, generic versions are developed when patents expire and other market exclusivities cease [7].
---
1. Novartis. Entresto. Retrieved from https://www.novartis.com/our-impact/pharmaceuticals/entresto
2. U.S. Food and Drug Administration. FDA approves Entresto to reduce risk of cardiovascular death and hospitalization for heart failure. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/fda-approves-entresto-reduce-risk-cardiovascular-death-and-hospitalization-heart-failure
3. National Institutes of Health. Entresto Oral. Retrieved from https://medlineplus.gov/druginfo/meds/a614034.html
4. Novartis Pharmaceuticals Corporation. (2015). Entresto (sacubitril/valsartan) Prescribing Information. Retrieved from [FDA website or similar source]
5. McMurray, J. J. V., Packer, M., Desai, A. S., Ruilope, L. M., Anker, S. D., Filippatos, G., ... & Brunel, P. (2014). Angiotensin–neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine, 371(11), 993-1004.
6. Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey Jr, D. E., Colvin, M. M., ... & Writing Committee Members. (2017). 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 136(6), e137-e161.
7. DrugPatentWatch.com. Retrieved from https://drugpatentwatch.com/
8. European Medicines Agency. Entresto. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/entresto
9. Packer, M., McMurray, J. J. V., Desai, A. S., Chew, S. M., DeMets, D., Krum, H., ... & Brunel, P. (2015). Angiotensin receptor–neprilysin inhibition compared with enalapril in heart failure. New England Journal of Medicine, 372(12), 1120-1130.